164 related articles for article (PubMed ID: 15170138)
1. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.
Tas F; Yasasever V; Duranyildiz D; Camlica H; Ustuner Z; Aydiner A; Topuz E
Am J Clin Oncol; 2004 Jun; 27(3):225-8. PubMed ID: 15170138
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta.
Juergensen A; Holzapfel U; Hein R; Stolz W; Buettner R; Bosserhoff A
Tumour Biol; 2001; 22(1):54-8. PubMed ID: 11054027
[TBL] [Abstract][Full Text] [Related]
3. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
4. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells.
Uslu U; Schliep S; Schliep K; Erdmann M; Koch HU; Parsch H; Rosenheinrich S; Anzengruber D; Bosserhoff AK; Schuler G; Schuler-Thurner B
Anticancer Res; 2017 Sep; 37(9):5033-5037. PubMed ID: 28870930
[TBL] [Abstract][Full Text] [Related]
6. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma].
Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J
Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179
[TBL] [Abstract][Full Text] [Related]
7. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma.
Deichmann M; Benner A; Bock M; Jäckel A; Uhl K; Waldmann V; Näher H
J Clin Oncol; 1999 Jun; 17(6):1891-6. PubMed ID: 10561230
[TBL] [Abstract][Full Text] [Related]
8. Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Lozano MD; Echeveste JI; Pérez Gracia JL; Alegre E; Carranza O; Zubiri L; Martín-Algarra S; González A
Clin Chim Acta; 2014 Feb; 429():168-74. PubMed ID: 24333389
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
10. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests.
Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM
Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538
[TBL] [Abstract][Full Text] [Related]
11. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
[TBL] [Abstract][Full Text] [Related]
12. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma.
Jury CS; McAllister EJ; MacKie RM
Br J Dermatol; 2000 Aug; 143(2):269-74. PubMed ID: 10951132
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of multiple serum markers in advanced melanoma.
Díaz-Lagares A; Alegre E; Arroyo A; González-Cao M; Zudaire ME; Viteri S; Martín-Algarra S; González A
Tumour Biol; 2011 Dec; 32(6):1155-61. PubMed ID: 21858537
[TBL] [Abstract][Full Text] [Related]
14. Serum markers to detect metastatic uveal melanoma.
Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
[TBL] [Abstract][Full Text] [Related]
15. Seropositivity for MIA and S100 in patients with gastrointestinal carcinomas.
Wagner V; Rudi J; Näher H; Stremmel W
Med Oncol; 2000 Feb; 17(1):35-8. PubMed ID: 10713658
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of serum S100 in metastatic malignant melanoma.
Guo HB; Stoffel-Wagner B; Bierwirth T; Mezger J; Klingmüller D
Eur J Cancer; 1995 Oct; 31A(11):1898-902. PubMed ID: 8541129
[TBL] [Abstract][Full Text] [Related]
17. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma.
Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R
Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043
[TBL] [Abstract][Full Text] [Related]
18. Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients.
Schmitz C; Brenner W; Henze E; Christophers E; Hauschild A
Anticancer Res; 2000; 20(6D):5059-63. PubMed ID: 11326668
[TBL] [Abstract][Full Text] [Related]
19. S100 protein serum levels in cutaneous malignant melanoma.
Seregni E; Massaron S; Martinetti A; Illeni MT; Rovini D; Belli F; Agresti R; Greco M; Cascinelli N; Bombardieri E
Oncol Rep; 1998; 5(3):601-4. PubMed ID: 9538159
[TBL] [Abstract][Full Text] [Related]
20. Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B.
Stoitchkov K; Letellier S; Garnier JP; Bousquet B; Tsankov N; Morel P; Ghanem G; Le Bricon T
Melanoma Res; 2002 Jun; 12(3):255-62. PubMed ID: 12140382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
